ClinicalTrials.gov
public full text
Public Domain
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa#1339795
- Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients#1194793
- Trophoblast Extracellular Vesicles Rewire Immunity: A Symptom‐Relief Avenue for Recessive Dystrophic Epidermolysis Bullosa#1415284
- Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds#1418293
- Fabrication of a five-layer wound dressing containing chitosan-LL37 peptide for the treatment of EB wounds and deep exudate patients.#631154
Record · ID 1483552
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive